Sort
4,870 grants matching “glp 1”
Disease Modifying Analgesia with CA8 Gene Therapy
$1,109,446Roy Clifford Levitt · University Of Miami School Of Medicine · UH3 · FY2023 · NS
A New Anti-inflammatory Therapy for Ischemic Stroke
$1,109,152Bruce Liang · Cornovus Pharmaceuticals, Inc. · R42 · FY2025 · HL
A novel approach for prevention of Bronchopulmonary dysplasia in at-risk pre-term infants
$1,109,134Suchismita Acharya · Ayuvis Research, Inc. · R44 · FY2022 · HD
IND-Enabling Pre-Clinical Studies to Accelerate the Clinical Development of a Humanized Anti-Cocaine Monoclonal Antibody
$1,108,943Andrew B Norman · University Of Cincinnati · U01 · FY2021 · DA
Small molecule inhibitory leads against influenza RdRp
$1,108,397Thomas Roy Webb · St. Jude Children'S Research Hospital · R01 · FY2012 · AI
Antibody immunotherapeutics for biodefense against Lassa virus
$1,105,698Robert F Garry · Tulane University Of Louisiana · R01 · FY2014 · AI
Lazzaro Medical Scaffold System for improved treatment of tracheobronchomalacia
$1,104,123Dawn Dawn Bitz · Lazzaro Medical, Inc. · R44 · FY2025 · HL
Prevention of arthritis-induced bone erosion by inhibiting osteoclast differentiation by the haloanilide, N-Methyl Dichloropropionaniline
$1,103,697John B Barnett · Exesalibero, Inc. · R42 · FY2020 · AR
Drugs Targeting Dormant Tumors as Anti-Metastatic Agents
$1,102,521Michael A Ihnat · Dormatarg, Inc. · R44 · FY2011 · CA
Optimizing Novel Dihydroorotate Dehydrogenase Inhibitors for Treating Malaria
$1,101,631Ian Cyril Bathurst · Medicines For Malaria Venture · U01 · FY2009 · AI
Oxadiazole Inhibitors of Non-Stop Ribosome Rescue to treat MDR Neisseria gonorrhoeae
$1,100,543Zachary David Aron · Microbiotix, Inc · R01 · FY2019 · AI
Novel AMPK activator for treatment of congenital X-linked nephrogenic diabetes insipidus in pediatric patients
$1,096,928Jeff M Sands · Nephrodi Therapeutics, Inc. · R44 · FY2025 · DK
Safety and Toxicology Studies of CLT-005 as a Therapeutic for Diabetic Macular Ed
$1,095,787Rafal A Farjo · Charlesson, Llp · R44 · FY2011 · EY
Medicinal Chemistry Optimization of Anti-Alphaviral Leads and Elucidation of Target and Off Target Engagement
$1,095,000Jennifer E. Golden · University Of Tennessee Health Sci Ctr · U19 · FY2019 · AI
Closed-loop neuroelectric control of emesis and gastric motility
$1,094,542Charles Christopher Horn · University Of Pittsburgh At Pittsburgh · U18 · FY2018 · TR
CEACAM5-targeted activation of potent chemotherapeutics via bioorthogonal click chemistry
$1,094,189Jose M Mejia Oneto · Shasqi, Inc. · R44 · FY2025 · CA
Production of a Hydrogel-based Mucosal Sealant for Gastrointestinal Bleeding Prevention
$1,094,074Gonzalo Munoz Taboada · Biodevek Inc · R44 · FY2025 · DK
Translational feasibility of an oral, non-hormonal, male contraceptive pill
$1,093,784Paul D Crowe · Orphagen Pharmaceuticals · R44 · FY2019 · HD
Novel PARS inhibitor for therapy of colitis
$1,092,059Inotek Pharmaceuticals Corporation · R44 · FY2001 · DK
Toxicology (IND-enabling) studies for a novel nerve imaging agent for prostate cancer
$1,090,970Stephen B Kahl · Manzanita Pharmaceuticals, Inc. · R44 · FY2025 · CA
Universal room temperature stable influenza nanovaccine
$1,090,313Balaji Narasimhan · Iowa State University · R01 · FY2022 · AI
Phase 2 Enabling Studies of a Candidate Drug Therapy (T3D-959) Regulating Neurometabolism for the Treatment of Huntington's Disease
$1,088,768John Didsbury · T3d Therapeutics, Inc. · R44 · FY2022 · NS
ALZHEIMERS RESEARCH PROJECT / CLINICAL PROJECT: Mechanistic and clinical studies in Alzheimer's disease and related disorders
$1,086,297Dimitrios Kapogiannis · National Institute On Aging · ZIA · FY2025 · AG
RBD recombinant protein-based SARS vaccine for biodefense
$1,085,321Peter J Hotez · Baylor College Of Medicine · R01 · FY2013 · AI
Drug Development of GLP-1 receptor agonists
$1,079,455Josephine M Egan · Aging · Z01 · FY2007 · AG